Sachdev Amit 4

What Happened Sachdev Amit, EVP, Chief Patient & External Affairs Officer at Vertex Pharmaceuticals (VRTX), was awarded a total of 11,749 shares (7,866 + 3,883) on 2026-01-22 as earned performance shares. The shares were reported as acquired at $0 (award/grant), reflecting performance-vested stock units rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-22; Form filed 2026-01-26 (reporting period 2026-01-22).
• Award details:
  • 7,866 shares (footnote F1) — from a PSU granted 02/01/2023; performance certified 01/22/2026; vesting date 02/13/2026.
  • 3,883 shares (footnote F2) — from a PSU granted 02/12/2025; performance certified 01/22/2026; vesting in installments beginning 02/24/2026.
• Acquisition price reported: $0 (stock awarded as compensation). Total shares awarded: 11,749.
• Shares owned after the transaction are not specified in the excerpt provided.

Context These transactions are awards of performance-based shares (code A) that reflect achievement of pre-set goals and will vest on the dates above; they are routine compensation actions, not open-market buying or selling. For retail investors, awards indicate compensation recognition but are not direct buy/sell signals.